<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83764">
  <stage>Registered</stage>
  <submitdate>29/03/2009</submitdate>
  <approvaldate>25/05/2009</approvaldate>
  <actrnumber>ACTRN12609000347268</actrnumber>
  <trial_identification>
    <studytitle>The optimal volume of ropivacaine for pain relief after shoulder surgery</studytitle>
    <scientifictitle>Optimising Analgesia after Shoulder Surgery:  the optimum primary volume and dose of ropivacaine for continuous interscalene analgesia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ISCVOL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pain relief after shoulder surgery</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Up down staircase method (sequential allocation of dose depending on the response of the previous patient) for determination of ED50 of both ropivacaine volume and concentration (administered by perineural injection) starting at 30 mL and 0.5%.
Once the ED95 for both the volume and concentration has been determined, this will be compared with ropivacaine 0.5% 30 mL.

This is a one-off injection in each patient.</interventions>
    <comparator>30mL 0.5% ropivacaine as single injection via an interscalene catheter prior to shoulder surgery lasting 1 hour</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Presence or absence of pain in the PACU as determined by the patients primary recovery nurse - direct patient interrogation.</outcome>
      <timepoint>In post anaesthesia care unit (PACU) for 30 min. Outcome assessed by direct patient interrogation.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Time to first onset of pain during first 24 hours</outcome>
      <timepoint>Once at 24 hours from treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Arm numbness/weakness (questionnaire)</outcome>
      <timepoint>Once during the first 24 hours on the afternoon of postoperative day 1.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Satisfaction (all with patient questionnaire)</outcome>
      <timepoint>First 24 hours postoperatively (once at 24 hours)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Grip strength using dynamometer</outcome>
      <timepoint>30 mins following emergence</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients requiring continuous interscalene analgesia for shoulder surgery under the care of the three investigators</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Patient refusal of block.  2. Known neuropathy involving the shoulder undergoing surgery. 3. Known allergy to amide local anaesthetic drugs.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Initial invitation to participate in the study will occur in the surgeon's rooms.  Approximately one week prior to surgery, patients will be contacted by a research assistant to provide further informed consent.  Written informed consent will be obtained from all patients.  Assignment of the patient to one of the 2 groups will be delivered in a sealed opaque envelope.</concealment>
    <sequence>A computerised random number generator will be used to assign the patient to one of the 2 groups.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>A two part study:
First part is to determine the ED95 with respect to volume and concentration of ropivicaine for the primary interscalene catheter bolus dose. The up-down sequential allocation method will be used. Second part is to determine whether this dose has any significant difference in duration to that of ropivacaine 0.5% 30 mL.</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/04/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Michael Fredrickson</primarysponsorname>
    <primarysponsoraddress>Anaesthesia Institute
P O Box 109 199
Newmarket
Auckland 1149</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>I-Flow International</fundingname>
      <fundingaddress>Lake Forrest, CA, USA 92630</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>If the primary hypothesis is confirmed, this study will provide evidence supporting the use of a lower primary bolus dose via the interscalene catheter prior to shoulder surgery.  Increased exposure of the techniques may promote their uptake in this setting.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern Y Regional Ethics Committee</ethicname>
      <ethicaddress>P O Box 1031
Hamilton
Waikato Mail Centre 3240</ethicaddress>
      <ethicapprovaldate>2/04/2009</ethicapprovaldate>
      <hrec>NTY/09/18/EXP</hrec>
      <ethicsubmitdate>9/03/2009</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Michael Fredrickson</name>
      <address>Anaesthesia Institute
P O Box 109 199
Newmarket
Auckland 1149</address>
      <phone>+64 9 522 1117</phone>
      <fax>+64 9 522 1127</fax>
      <email>aiservice@xtra.co.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Michael Fredrickson</name>
      <address>Anaesthesia Institute
P O Box 109 199
Newmarket
Auckland 1149</address>
      <phone>+64 9 522 1117</phone>
      <fax>+64 9 522 1127</fax>
      <email>aiservice@xtra.co.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Margaret Watkin</name>
      <address>Anaesthesia Institute
P O Box 109 199
Newmarket
Auckland 1149</address>
      <phone>+64 9 522 1117</phone>
      <fax>+64 9 522 1127</fax>
      <email>aiservice@xtra.co.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>